Pioglitazone

Generic Name: Pioglitazone

Brand Names: Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₀N_₂O_₃S

CAS Number: 111025-46-8

Unique Ingredient Identifier: X4OV71U42S

Background: Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medicatio...

Indication: Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.

Associated Conditions: Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

Normal-weight Diabetes: Adipocyte-directed Therapy with Pioglitazone or Tirzepatide

Phase 4

Not yet recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Procedure: Insulin resistance testing
Procedure: OGTT
Procedure: Fat biopsy
Radiation: DXA scan
Procedure: MRI
Procedure: 1H-MRS
Drug: Tirzepatide
Drug: Pioglitazone

First Posted Date: 2024-10-24

Last Posted Date: 2024-10-24

Lead Sponsor: Stanford University

Target Recruit Count: 104

Registration Number: NCT06657209

Locations: 🇺🇸
Stanford University, Clinical and Translational Research Unit (CTRU), Stanford, California, United States

Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

Phase 4

Recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Enavogliflozin
Drug: Pioglitazone

First Posted Date: 2024-05-06

Last Posted Date: 2024-05-06

Lead Sponsor: Seoul National University Bundang Hospital

Target Recruit Count: 120

Registration Number: NCT06399835

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

Phase 3

Not yet recruiting

Conditions: Type 2 Diabetes (Adult Onset)

Interventions: Drug: Tirzepatide
Drug: Sitagliptin
Drug: Metformin HCI XR
Drug: Pioglitazone

First Posted Date: 2024-02-07

Last Posted Date: 2024-10-09

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 730

Registration Number: NCT06246799

Locations: 🇺🇸
University Health System Texas Diabetic Institute, San Antonio, Texas, United States

Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants

Phase 4

Recruiting

Conditions: Type 2 Diabetes Mellitus in Obese
Heart Failure With Preserved Ejection Fraction

Interventions: Drug: Pioglitazone
Drug: Placebo

First Posted Date: 2023-05-01

Last Posted Date: 2024-08-20

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 78

Registration Number: NCT05838287

Locations: 🇺🇸
Texas Diabetes Institute/UH, San Antonio, Texas, United States

A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.

Early Phase 1

Recruiting

Conditions: Hyperinsulinism
Hyperglycemia Drug Induced
Metastatic Breast Cancer

Interventions: Drug: Pioglitazone

First Posted Date: 2023-03-03

Last Posted Date: 2023-03-03

Lead Sponsor: Rambam Health Care Campus

Target Recruit Count: 30

Registration Number: NCT05753657

Locations: 🇮🇱
Rambam Health Care Campus, Haifa, Israel

Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease

Conditions: Type 2 Diabetes Mellitus With Complication

Interventions: Drug: Pioglitazone
Drug: Canagliflozin

First Posted Date: 2022-08-24

Last Posted Date: 2022-08-24

Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Target Recruit Count: 80

Registration Number: NCT05513729

Locations: 🇨🇳
First Affiliated Hospital Xi'an Jiaotong University, Xi'an, Shannxi, China

Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease

Not Applicable

Conditions: Type 2 Diabetes Mellitus With Complication

Interventions: Drug: Canagliflozin
Drug: Pioglitazone

First Posted Date: 2022-06-16

Last Posted Date: 2022-09-21

Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Target Recruit Count: 80

Registration Number: NCT05422092

A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS)

Phase 2

Recruiting

Conditions: Polycystic Ovary Syndrome (PCOS)

Interventions: Drug: Placebo
Drug: Pioglitazone
Drug: Spironolactone
Drug: Metformin

First Posted Date: 2022-05-27

Last Posted Date: 2024-04-22

Lead Sponsor: Fundació Sant Joan de Déu

Target Recruit Count: 364

Registration Number: NCT05394142

Locations: 🇮🇹
Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy
🇪🇸
Hospital Sant Joan de Deu, Esplugues De Llobregat, Spain
🇪🇸
Hospital Universitari de Girona Dr. Trueta, Girona, Spain

and more 4 locations

Quantifying Hepatic Mitochondrial Fluxes in Humans

Phase 4

Recruiting

Conditions: Non-Alcoholic Fatty Liver Disease
Type 2 Diabetes
Mitochondrial Metabolism Disorders

Interventions: Other: Placebo
Drug: Pioglitazone

First Posted Date: 2022-03-31

Last Posted Date: 2024-08-30

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 60

Registration Number: NCT05305287

Locations: 🇺🇸
Texas Diabetes Institute - University Health System, San Antonio, Texas, United States
🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

Effects of Pioglitazone on Stress Reactivity and Alcohol Craving

Phase 1

Recruiting

Conditions: Alcohol Use Disorder

Interventions: Drug: Placebo
Drug: Pioglitazone

First Posted Date: 2021-11-04

Last Posted Date: 2024-01-24

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 60

Registration Number: NCT05107765

Locations: 🇺🇸
The University of Texas Health Science Center of Houston, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy